AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease

The company has "received Import and Market Permission in Form CT-20
(Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets
10 mg," AstraZeneca Pharma India said in a filing to BSE.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazenecas-dapagliflozin-tablets-get-dcgi-nod-for-patients-with-chronic-kidney-disease/articleshow/80722914.cms

Comments

Popular posts from this blog

Freshers Job: Life Sciences Associate – Claims Vacancy at Genpact

Piramal Pharma Program Associate Vacancy Available